Heart-specific antibodies as modulators of myocardial infarction (B6)

Antibodies are causally linked to the progression of ischemic heart failure. Yet, conventional serological approaches have thus far failed to identify what cardiac antigens are targeted by antibodies and provide key mechanistic details regarding how they impact myocardial disease progression.

Antibodies in myocardial infarction

Recent studies from our groups and from others have revealed that myocardial infarction and heart failure elicit the production of heart-specific antibodies, which associate with a poorer disease outcome both in mice and humans. Nevertheless, the specificities of the antibodies produced in response to cardiac injury and the mechanisms by which they impact myocardial biology remain largely unknown.

Rationale and aims

We will seek to track the B-cells activated after myocardial infarction and to characterise the antibodies produced by them.


We will complementarily use high-end multi-colour fluorescence approaches such as intravital and light-sheet fluorescence microscopy, multicolour flow cytometry and single-cell sequencing to track and phenotype the “rare-but-right” antigen-specific B-cells activated after myocardial infarction in mice and patients.

Significance and outlook

We expect that this approach will enable us to identify for the first time the MI-triggered antibodies and to produce them in vitro for mechanistic studies.


Portrait of Prof. Dr. rer. nat. Katrin Heinze

Prof. Dr. rer. nat.
Katrin Heinze

Leader of the CRC project B6

+49 931 31-84214

Portraitfoto PhD Gustavo Ramos

Prof. Dr. rer. nat.
Gustavo Ramos

Leader of the CRC projects A3 and B6

+49 931 201-46477


Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Zentrum für Innere Medizin (ZIM), Oberdürrbacher Straße 6, Haus A3, 97080 Würzburg, Deutschland 

Deutsches Zentrum für Herzinsuffizienz Würzburg | Comprehensive Heart Failure Center | Am Schwarzenberg 15 | Haus A15 | 97078 Würzburg